Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Palovarotene for the Treatment of MO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written, signed, and dated informed subject/parent consent and age-appropriate assent (performed according to local regulations).~* A clinical diagnosis of MO with disease-causing exostosin 1 or 2 gene mutations.~* Male or female from 2 to 14 years of age.~* Female subjects must be premenarchal at screening.~* A bone age at screening of 14 years or less.~* Symptomatic MO, defined as five or more clinically evident osteochondromas and a new or enlarged osteochondroma that occurred in the preceding 12 months, five or more clinically evident osteochondromas and the presence of a painful osteochondroma, a skeletal deformity, a joint limitation, or prior surgery for a MO-related complication.~* The ability to undergo whole body MRI with or without sedation/general anesthesia.~* Use of two effective methods of birth control during treatment, and for 1 month after treatment discontinuation, unless committed to true abstinence from heterosexual sex. Sexually active females of child-bearing potential must also agree to start effective methods of birth control at screening.~Key Exclusion Criteria:~* Weight under 10 kg.~* Other syndromic conditions such as Langer-Giedion or Potocki-Shaffer.~* Any subject with neurologic signs suggestive of spinal cord impingement.~* Concomitant medications that are strong inhibitors or inducers of cytochrome P450 3A4 activity.~* Amylase or lipase \>2 times the above the upper limit of normal (\>2×ULN) or with a history of chronic pancreatitis.~* Elevated aspartate aminotransferase or alanine aminotransferase above 2.5×ULN.~* Any surgical implant that is contraindicated for MRI.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Palovarotene 2.5 mg daily regimen (Type: EXPERIMENTAL): None
- Palovarotene 5.0 mg daily regimen (Type: EXPERIMENTAL): None
- Placebo regimen (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).